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Exposure to chlorination disinfection by-products (CxDBPs) is prevalent in populations using
chlorination-based methods to disinfect public water supplies. Multifaceted research has been
directed for decades to identify, characterize, and understand the toxicology of these com-
pounds, control and minimize their formation, and conduct epidemiologic studies related
to exposure. Urinary bladder cancer has been the health risk most consistently associated
with CxDBPs in epidemiologic studies. An international workshop was held to (1) discuss
the qualitative strengths and limitations that inform the association between bladder can-
cer and CxDBPs in the context of possible causation, (2) identify knowledge gaps for this
topic in relation to chlorine/chloramine-based disinfection practice(s) in the United States,
and (3) assess the evidence for informing risk management. Epidemiological evidence linking
exposures to CxDBPs in drinking water to human bladder cancer risk provides insight into
causality. However, because of imprecise, inaccurate, or incomplete estimation of CxDBPs
levels in epidemiologic studies, translation from hazard identification directly to risk man-
agement and regulatory policy for CxDBPs can be challenging. Quantitative risk estimates
derived from toxicological risk assessment for CxDBPs currently cannot be reconciled with
those from epidemiologic studies, notwithstanding the complexities involved, making regula-
tory interpretation difficult. Evidence presented here has both strengths and limitations that
require additional studies to resolve and improve the understanding of exposure response
relationships. Replication of epidemiologic findings in independent populations with further
elaboration of exposure assessment is needed to strengthen the knowledge base needed to
better inform effective regulatory approaches.
BACKGROUND
Disinfection by-products (DBPs) in drinking
water were discovered more than 40 years ago
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(Rook 1974; Bellar et al. 1974) in the form of
trihalomethanes (THMs), including chloroform,
bromodichloromethane (BDCM), dibro-
mochloromethane (DBCM), and bromoform.
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This transformational discovery was followed by
findings that chloroform was carcinogenic in
rodents (National Cancer Institute [NCI] 1976),
leading to the banning of chloroform use in
a wide range of consumer products such as
cough syrups, antihistamines, decongestants,
and cosmetics (National Toxicology Program
[NTP] 2013). The first THM regulatory initia-
tive under the 1974 Safe Drinking Water Act
appeared in 1979, specifying a limit of 100
µg/L for a mass concentration sum of the
4 THMs (THM4) as a running annual average of
4 quarterly samples, citing a concern for long-
term cancer risk (U.S. Environmental Protection
Agency [EPA] 1979). Crump and Guess (1982)
summarized the early epidemiologic evidence
exploring chlorinated drinking water and can-
cer risk.
Following the initial discovery of THMs in
drinking water, more than 600 new DBPs with
varying degrees of toxicity and potential can-
cer risk have been discovered (Richardson et al.
2007; 2008). DBPs are produced to some
degree by any chemical disinfection process,
but those produced by disinfection processes
involving chlorine, including chloramination,
attracted the most attention. In this review,
DBPs produced by disinfection processes
involving chlorine (excluding chlorine diox-
ide) are collectively termed chlorination DBPs
(CxDBPs) because these chemicals are formed
by chlorine-based disinfectants. Although chlor-
amination is known to yield lower THM4 pro-
duction, the impact is highly dependent on
free chlorine contact time before ammonia
addition and overall water quality such as lev-
els of total organic carbon and/or bromide.
CxDBPs do not necessarily contain chlorine and
include non-halogenated nitrogenous DBPs like
nitrosamines.
Numerous cancer sites have also been
evaluated for association with chlorinated
drinking water (Mills et al. 1998), includ-
ing two IARC reviews of the evidence for
the following specific CxDBPs: chloramines,
chloral, chloral hydrate, dichloroacetic acid,
trichloroacetic acid, and MX (IARC 2004),
and bromochloroacetic acid, dibromoacetic
acid, and dibromoacetonitrile (IARC 2013).
To date, epidemiologic evidence related to
urinary bladder cancer exhibited the greatest
consistency (U.S. EPA, 2006a), and bladder can-
cer was a key aspect of the cost–benefit analysis
for the Stage 2 DBP Rule (U.S. EPA 2006b).
PUBLIC HEALTH RELEVANCE OF
BLADDER CANCER IN THE UNITED
STATES
Bladder cancer is an important public
health issue, causing the fifth highest number
of estimated new U.S. cases of cancer in 2015
(American Cancer Society 2015) for both gen-
ders, accounting for about 74,000 new cases
out of about 1.66 million new cases for all can-
cer sites. Bladder cancer accounted for approxi-
mately 16,000 estimated deaths out of the total
of about 590,000 U.S. deaths for all cancer sites
in 2015. The risk for bladder cancer rises expo-
nentially with age over 40 yr. The U.S. median
age at diagnosis is 73 yr, with 91% of new cases
incident after age 55, 72% after 65, and 45%
after 75 (SEER 2015). In the United States, blad-
der cancer is currently threefold more common
in men than women.
Risk factors for bladder cancer include
exposures to tobacco smoke, occupational
chemicals, certain cancer treatments includ-
ing drugs such as cyclophosphamide, radiation
therapy to the abdomen or pelvis, and arsenic
in drinking water. Other risk factors are listed
as family history of bladder cancer and per-
sonal history of bladder cancer for possible
recurrence (NCI 2004).
OBJECTIVES
The Water Research Foundation and the
American Water Works Association commis-
sioned an interdisciplinary panel review to
evaluate the scientific evidence concerning
the association of chlorination disinfection by-
products (CxDBPs) and human bladder cancer.
The panel was asked to address three funda-
mental questions regarding DBPs:
1. What are the qualitative strengths and lim-
itations of the evidence for known and/or
unidentified CxDBPs that inform causality of
human urinary bladder cancer?
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2. What critical knowledge gaps exist for
explaining human urinary bladder cancer
risk in relation to drinking water chlorine
and/or chloramine-based disinfection prac-
tice(s) in the United States?
3. Does the available evidence support a quan-
titative and qualitative analysis of CxDBP
risk management strategies that will be more
accurate and informative for guiding risk
management than previously possible with
evidence available for developing the cur-
rent Stage 2 DBP Rule?
The primary outcome of the expert panel work-
shop was an evidence review, published as a
Water Research Foundation research report
that incorporated inputs from the workshop,
with a comprehensive summary of supporting
evidence, what knowledge is lacking, and
a summary of viable options for gaining the
missing evidence (Interdisciplinary Expert Panel
2015).
METHODS
A draft background paper was prepared
by Hrudey, outlining the issues and avail-
able evidence addressing the objectives of the
project, and was provided to the expert panel
(Backer, Hrudey, Humpage, Krasner, Michaud,
Moore, Singer, and Stanford) electronically
10 days before an in-person, 2-day workshop,
March 24 and 25, 2014, in Washington, DC.
The background paper for the panel workshop
was developed from a comprehensive litera-
ture search of major databases including Web
of Science, Medline, EMBASE, Global Health,
Toxline, Pollution Abstracts, Water Resource
Abstracts, Cochrane Library, BIOSIS previews,
and Scopus. Manual searching of bibliogra-
phies of the relevant papers identified was
performed. Tracking citations of major relevant
papers using Web of Science was also pursued.
In addition to the literature search results, the
background paper review was built upon and
compared with coverage from several earlier
reviews that included some of the objective
topics (Hrudey 2008; Hrudey et al. 2003; IARC
2004; 2013; Mills et al. 1998; Sinclair et al.
2002; U.S. EPA 2006). The evidence available
to deliberations for the Stage 2 DBP Rule was
briefly reviewed and taken as the starting point
for reviewing new, relevant evidence. This pro-
vides the framework for this current paper.
Classification of exposure to CxDBPs for
epidemiologic studies was considered in some
detail because of the inherent challenges posed
by estimating CxDBP exposures among indi-
viduals over several decades to address an
estimated bladder cancer latency period, which
typically exceeds 30 years. A summary of expo-
sure assessment challenges for drinking water
epidemiology was provided in Table 3 of the
paper by Villanueva et al. (2014). Several
aspects of estimating DBP exposures were pre-
viously suggested by Arbuckle et al. (2002),
which generated numerous recommendations
for improved assessment that might be useful
for short-term DBP exposures mostly meaning-
ful for studying effects like adverse reproductive
outcomes. Arbuckle et al. (2002) suggested
few practical options, beyond improved DBP
occurrence models, for enhancing long-term,
retrospective exposure assessments required for
cancer epidemiology.
As long as associations are large enough to
be demonstrated, epidemiologic study results
suffering from exposure misclassification or
quantitative inaccuracy can still provide useful
evidence toward an evaluation of consistency
of association and potentially for informing
causal inference. However, from the perspec-
tive of those who must regulate exposures
to minimize potential health risks in drink-
ing water, quantitatively inaccurate exposure
assessment has serious implications if used for
quantitative risk assessment to inform regu-
lation. If true DBP exposures are under- or
overestimated, the level of CxDBPs associ-
ated with elevated cancer risk may not accu-
rately reflect the actual exposure levels asso-
ciated with the health outcome. These issues
are developed further in the following for the
purposes of interpreting epidemiologic stud-
ies in our discussion of Amy et al. (2006).
Further, for the purposes of supporting regula-
tion, the most common quantitative measures
of DBP exposure in epidemiologic studies may
only be a surrogate that correlates with an
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unknown causal agent(s) (e.g., THM4 serving
as a surrogate for unknowns). Therefore, with-
out developing further knowledge, it is unclear
whether mitigation measures, such as treatment
for a surrogate marker, will reduce exposures
to causal agent(s) when the strength of correla-
tion between them and/or relative amenability
to removal may vary. For example, if the focus is
on brominated compounds and THM4 is a sur-
rogate, many of the bromine-containing DBPs
will have different amenability to formation or
removal than THM4, which is primarily chloro-
form. Conventional coagulation and advanced
treatment processes such as granular activated
carbon remove total organic carbon but not
bromide (Summers et al. 1993; Watson et al.
2015), so the proportion of brominated DBPs
(brominated THMs, brominated HAAs, etc.)
might increase even though total THM4 may
be reduced. If the focus is on HAAs, removal
of the semivolatile THM4 by aeration may not
accurately represent removal of the nonvolatile
HAAs because they have different physical–
chemical properties. In either illustration, the
behavior through treatment processes of bromi-
nated DBPs or HAAs might not be accurately
represented by class sums like THM4.
RESULTS AND DISCUSSION
Epidemiologic Evidence
Previous Studies and Findings Published
(1974–2004) The U.S. EPA relied primarily
upon five incident case-control studies focused
on bladder cancer for assessing the health bene-
fits of the Stage 1 DBP Rule (Cantor et al. 1987;
1998; McGeehin et al. 1993; King and Marrett
1996; Freedman et al. 1997). For the final
Stage 2 DBP Rule health benefits assessment,
the U.S. EPA (2006) also included consideration
of a meta-analysis by Villanueva et al. (2003a)
performed on six case-control studies (Cantor
et al. 1987; 1998; McGeehin et al. 1993; Vena
et al. 1993; King and Marrett 1996; Koivusalo
et al. 1998) and two cohort studies (Wilkins
and Comstock 1981; Doyle et al. 1997), and a
pooled analysis by Villanueva et al. (2004) that
included six case-control studies (Lynch et al.
1989; Cordier et al. 1993; King and Marrett
1996; Cantor et al. 1998; Koivusalo et al. 1998;
Porru 2003 [an unpublished Italian study]).
The U.S. EPA (2006a) determined for its
evidence review for setting the Stage 2 DBP
Rule:
Based on a collective evaluation of both the human
epidemiology and animal toxicology data on cancer
and reproductive and developmental health effects
discussed below and in consideration of the large
number of people exposed to chlorinated byprod-
ucts in drinking water (more than 260 million), EPA
concludes that (1) new cancer data since Stage
1 strengthen the evidence of a potential associa-
tion of chlorinated water with bladder cancer and
suggests an association for colon and rectal cancers,
(2) current reproductive and developmental health
effects data do not support a conclusion at this
time as to whether exposure to chlorinated drink-
ing water or disinfection byproducts causes adverse
developmental or reproductive health effects, but
do support a potential health concern, and (3) the
combined health data indicate a need for public
health protection beyond that provided by the Stage
1 DBPR.
This finding was expanded to explain:
Human epidemiology studies and animal
toxicology studies have examined associations
between chlorinated drinking water or DBPs and
cancer. While EPA cannot conclude there is a causal
link between exposure to chlorinated surface water
and cancer, EPA believes that the available research
indicates a potential association between bladder
cancer and exposure to chlorinated drinking water
or DBPs.
The U.S. EPA concluded: “Overall, bladder can-
cer data provide the strongest basis for quanti-
fying cancer risks from DBPs.” These findings
are reasonable for the evidence base that was
available for precautionary regulatory purposes.
In performing its review of the
epidemiologic data, the U.S. EPA referred to
causal criteria, including consistency, strength
and specificity of association, temporality
(exposure precedes outcome), a biological
gradient (dose-response relationship), biolog-
ical plausibility, and coherence with multiple
lines of evidence—criteria that can be traced
to those originally proposed by Bradford-Hill
(1965). In addition, the U.S. EPA also consid-
ered the reliability of exposure data, statistical
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power and significance, and freedom from bias
and confounding. These factors and criteria
were considered in our following review of
the more recent epidemiologic evidence for its
strengths and limitations.
Recent Studies (Years 2004–2014) Our
panel focused primarily on evidence that
became available after publication of stud-
ies just cited. Amy et al. (2006) performed
an updated exposure assessment for two of
the previous studies (Cantor et al. 1998; King
and Marrett 1996) by applying expert knowl-
edge regarding formation of CxDBPs to use
available water quality and DBP data to bet-
ter model past exposures, improve exposure
assessment for THMs, and add estimates for
selected CxDBPs. Amy et al. (2006) noted that
exposure misclassification is inevitable in stud-
ies that attempt to estimate exposures that
occurred decades earlier, but that such misclas-
sification may likely be nondifferential (i.e., no
difference between cases and controls) unless
an unrecognized bias has occurred.
Amy et al. (2006) expanded the scope
of the exposure assessment, making better-
informed predictions of historical THM4 occur-
rence for each of these studies, based on greater
water quality detail from accessible site-specific
monitoring databases. These approaches pro-
vided for significantly more discrimination at
higher estimated exposures in the Cantor et al.
(1998) study. In the original Cantor et al. (1998)
investigation, the assigned maximal average
THM4 exposure was 74 µg/L, whereas in the
reanalysis the maximal lifetime average expo-
sure was 154 µg/L. In the historical monitoring
database, which was collected following the
1979 THM rule, the 75th and 95th percentile
and maximum THM4 concentrations were 46,
96, and 219 µg/L, respectively (Amy et al.
2006). In the original analysis, the odds ratio
(OR) values were significant for the two highest
assigned exposure categories, which included
the 90th and 95th percentiles (32.6–46.3 µg/L
and >46.4 µg/L) for males. However, using the
same cutoff points for the categories, but based
on more detailed and better-informed expo-
sure estimates, only the highest category (>46.4
µg/L) remained statistically significant (Table 1).
In the reanalysis that provided a new dis-
tribution of exposure, the 97.5th percentile
(exposure categories were assigned for defined
percentiles of the controls) of lifetime average
THM4 was >96.1 µg/L (Table 2), and it was
only at this level that there was a significant
OR. By comparison, as noted earlier, in the
reanalysis based on the original cutoff points
of exposure (Table 1), only lifetime average
THM4 exposure above 46.4 µg/L showed a
significant OR. This is an important distinction,
given that the current U.S. regulatory level for
THM4 is a maximum locational annual average
of 80 µg/L and there is an operational tar-
get1 THM4 average of 80% of that limit, that
is, 64 µg/L (Roberson et al. 1995). The reclas-
sification in Table 2 resulted in a wider range
for estimated exposure, which, being based on
the monitoring database, is more representa-
tive of the true THM4 exposure. The cutoff
points used in Table 2 resulted in a smaller num-
ber of cases in the higher exposure categories,
which also led to more imprecision in the point
estimates for these categories.
The Amy et al. (2006) reanalysis of the
King and Marrett (1996) study demonstrated
lower bladder cancer risks, with wider confi-
dence intervals (CI), and without a consistent
exposure-response pattern for THM4 exposure
(Table 3). These data are for men and women.
Unlike Cantor et al. (1998), women showed
higher bladder cancer risk than men in King and
Marrett (1996).
Four “newer” studies include Chevrier et al.
(2004), Villanueva et al. (2006, 2007), Bove
et al. (2007), and Cantor et al. (2010). Chevrier
et al. (2004) performed a somewhat unique
study addressing bladder cancer because they
assessed ozone disinfection, either alone or in
combination with chlorination, an important
distinction because ozone produces substan-
tially different DBPs than chlorination. They
used data from an incident, hospital-based,
case-control study in France performed almost
1An operational target is a value that governs normal oper-
ations of the water treatment plant so this is the highest con-
centration of THM4 that any treatment plant should normally
produce.
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TABLE 1. Comparison of Risk Estimates (ORs) of Bladder Cancer for Males in Cantor et al. (1998): Original Analysis Versus Reanalysis
(Amy et al. 2006)
Lifetime average THM4∗ Cases/controls Original analysis Cases/controls Reanalysis
≤0.7 269/501 1.0 (reference) 347/592 1.0 (reference)
0.8-2.2 244/314 1.27 (1.00–1.60) 107/157 1.02 (0.80–1.40)
2.3–8.0 123/188 1.14 (0.85–1.50) 156/212 1.09 (0.80–1.40)
8.1–32.5 133/194 1.11 (0.80–1.50) 150/230 1.02 (0.80–1.30)
32.6–46.3 53/54 1.67 (1.10–2.60) 24/28 1.32 (0.70–2.40)
≥46.4 53/57 1.53 (1.00–2.40) 83/85 1.46 (1.03–2.10)
∗Exposure categories based on 35th, 60th, 75th, 90th, and 95th percentiles in distribution among controls of lifetime average THM4 as
estimated in the original analysis.
TABLE 2. Risk Estimates (ORs) of Bladder Cancer for Males in
Cantor et al. (1998): New Exposure Categories in Reanalysis (Amy
et al. 2006)
Lifetime average (50 yr)
THM4∗ Cases/controls Reanalysis
≤0.5 294/510 1.0 (reference)
0.6–8.4 341/442 1.13 (0.91–1.40)
8.4–36.1 179/264 1.04 (0.80–1.30)
36.2–58.0 38/47 1.15 (0.70–1.80)
58.1–96.1 46/51 1.31 (0.80–2.10)
>96.1 30/26 1.80 (1.02–3.20)
∗Exposure categories based on 35th, 70th, 90th, 93.75th, and
97.5th percentiles in distribution among controls.
20 years earlier (1985–1987). Some important
qualifiers noted by Chevrier et al. (2004)
included having a “high” percentage exclu-
sion (63%) from the initial sample as a result
of missing data, a “modest” total sample size
(281 cases, 240 male, 41 female), and a need
for more detailed knowledge of the charac-
teristics of raw water before their findings
might be generalized to any type of water
source. However, Chevrier et al. (2004) yielded
some intriguing results with small case num-
bers (total available for all exposures of 281),
suggesting that exposure to ozonated water
(91 cases) exhibited a lower bladder can-
cer risk than exposure to chlorinated water
(112 cases).
Bove et al. (2007) published a case-control
study based on data originally reported by Vena
et al. (1993) for cases and controls collected
between 1979 and 1985, which reported only
fluid consumption data. Residential address
was used to estimate individual THM4 expo-
sure levels. Bove et al. (2007) found significant
associations for three of four THMs (chloroform,
bromodichloromethane, and bromoform), but
given the low relative carcinogenic potency in
animal studies of these THMs and low THM
exposure levels measured, these agents do not
provide plausible explanation of the cancer risk
observed in this study. The main limitations
of Bove et al. (2007) are the small sample
size, limited explanation of how the retrospec-
tive exposure assessment was conducted, and
difficulty in reconciling OR observations for
bromoform (except as a surrogate for uncharac-
terized brominated DBPs) and chloroform with
what is known regarding their low cancer risks.
A series of papers by Villanueva and col-
leagues (2003b; 2006; 2007) was published
on a comparatively large (1219 cases, 1271





THM4 >50 µg/L Cases/controls
Reanalysis, mean
THM4 >40 µg/L
≤10 years 253/650 1.0 (reference) 593/1310 1.0 (reference)
10–19 years 226/519 1.10 (0.87–1.38) 23/ 51 1.21 (0.71–2.05)
20–34 years 163/297 1.36 (1.05–1.76) 30/68 1.01 (0.63–1.60)
≥35 years 54/79 1.63 (1.08–2.46) 43/65 1.36 (0.90–2.07)
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controls) hospital-based incident case-control
study on bladder cancer (1998–2001), also
referred to here as the Spanish Bladder Cancer
Study (SBCS). This study provided a num-
ber of important advances, including additional
exposure assessment, explicit consideration of
inhalation and bathing exposure, and inclusion
of some water supplies with high proportions of
brominated THM species.
In the SBCS exposure assessment, 200 local
authorities and 150 water companies were
contacted to obtain relevant data. Annual
average THM4 levels and water source his-
tory since 1920 were determined and/or esti-
mated for 78.5% of the total study person-
years of exposure. New THM4 data were
obtained for 113 samples between September
and December 1999 to cover the geographic
regions in the study (Villanueva et al. 2003b).
Historical THM4 levels were assumed to remain
unchanged for treated water from a given water
source, and, on this basis, THM4 exposures
were extrapolated back to 1920. The levels
of THM4 exposure presented for many of the
chlorinated water supplies are likely to be a seri-
ous underestimation. Actual THM4 exposures
were most likely higher before the discovery of
THMs in chlorinated drinking water and their
reported adverse health effects, findings that
led to lowering of THM4 concentrations to sat-
isfy new drinking-water guidance (Health and
Welfare Canada 1978; U.S. EPA 1979; World
Health Organization [WHO] 1984) from the
early 1980s followed by a European Union [EU]
Directive in 1998 (EU 1998).
A major finding of this study was a clear,
significant association of male bladder can-
cer with estimated average residential THM4,
expressed as micrograms per liter (Table 4). The
evidence of an association based on average
exposure of THM4 via ingestion, expressed as
micrograms per day, for men did not exhibit a
stronger association than was found when using
THM4 concentration or duration of exposure to
chlorinated drinking water. Showering/bathing
duration data, weighted by average residential
THM4 level (min/d × µg/L), also produced
significant exposure-related increasing OR for
men.
TABLE 4. Bladder Cancer Odds Ratio in Relation to Residential




(95% CI) p Trend
≤8 µg/L 137/172 1.0 (reference)
>8.0–26.0 µg/L 140/158 1.53 (0.95–2.48)
>26.0–49 µg/L 183/160 2.34 (1.36–4.03)
>49 µg/L 158/180 2.53 (1.23–5.20) p < .01
Because the toxicological evidence does
not support an association between cancer risk
and chloroform at or below current U.S. regula-
tory THM4 levels from drinking water ingestion
(Bull et al. 1986; Butterworth and Bogdanffy
1999; U.S. EPA 2000), the possible carcino-
genic contributions from brominated THMs
may be critical if THMs are to be consid-
ered important with respect to cancer risk.
Moreover, in waters with a majority of bromi-
nated THMs, there will be higher levels of
brominated species of other classes of DBPs
(Krasner et al. 2006). Further, for U.S. cities with
moderate (∼0.1 mg/L) to high (∼0.5 mg/L)
levels of bromide in their source waters (Amy
et al. 1994), the proportion of bromine species
is generally not as high as that detected in cer-
tain parts of Spain (e.g., 0.5–1.2 mg/L in the
Llobregat River, a major source of water for
Barcelona, Spain; GE Power & Water 2010)
because the bromide concentrations in the
United States are typically lower than those
found in certain cities in Spain that were used in
Villanueva et al. (2007). In Barcelona, Alicante,
and Tenerife, Spain, the weight percentages of
THM4 containing bromine were 69, 84, and
95%, respectively, and weight percentages of
the sum of 9 HAAs containing bromine were
61, 55, and 79%, respectively (Villaneuva et al.
2007). The average concentration of dibro-
moacetic acid in these three Spanish cities was
6.5, 5.2, and 1.3 µg/L, in contrast to a major
U.S. nationwide survey (McGuire et al. 2002) in
which the median occurrence of dibromoacetic
acid was zero. Further, many high-bromide
waters in the United States use chloramines as
a secondary disinfectant, whereas free chlorine
is still the final disinfectant in Spain. Because of
these factors, much of the THM4 occurrence in
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some of the Spanish cities exceeds typical post-
Stage 2 DBP Rule THM4 levels in the United
States.
Genotyping Applied to Epidemiologic
Studies
Cantor et al. (2010) reported one of the
first evaluations of THM exposure and bladder
cancer risk to determine whether susceptible
subpopulations could be identified by nine
polymorphic variants in five genes using expo-
sure data from the SBCS case-control study.
Genes that encode these enzymes are poly-
morphic in human populations, resulting in
modified enzyme activity. Comparatively, blad-
der cancer risk might be higher or lower among
a subgroup of individuals carrying a certain
genotype upon exposure to CxDBPs when
compared to the group lacking this genotype.
Variants in NAT2, GSTM1, GSTT1, GSTZ1, and
CYP2E1 were selected for identification of sus-
ceptible subpopulations in this study using
current knowledge of their role in CxDBPs
metabolism, bladder cancer risk, and variant
allele prevalence among population controls.
Cantor et al. (2010) used all exposure assess-
ment data and exposure modeling previously
reported by Villaneuva et al. (2007) among a
subset of subjects (680 cases/714 controls) who
were successfully genotyped.
The conceptual model guiding selection of
GSTT1 as one of the genes that may con-
tribute to variability in the susceptibility to blad-
der cancer evaluation undertaken by Cantor
et al. (2010) was based on brominated THMs
being mutagenic, carcinogenic, and prevalent
in chlorinated drinking water containing bro-
mide. Briefly, this concept (Richardson et al.
2007) focused on dermal absorption or inhala-
tion, whereby these CxDBPs escape first-pass
hepatic metabolism and reach target tissues in
the urinary tract where GSTT1-mediated acti-
vation may be favored over other metabolism
(Landi et al. 1999; Ross and Pegram 2003;
2004). Leavens et al. (2007) showed that
dermal exposure to bromodichloromethane
(BDCM) resulted in blood levels 25- to 130-
fold higher than those from oral exposure.
GSTT1 metabolizes small halogenated com-
pounds, among many others, and GSTT1 conju-
gation by the active variant is required for bio-
activation into reactive metabolites (Ginsberg
et al. 2009).
Considering only the THMs, the concepts
proposed for this model suggest that dermal
and inhalation exposure routes for DBP expo-
sure may result in higher exposures of urinary-
tract target tissue than exposure via ingestion.
This finding is consistent with Villanueva et al.
(2007), who found that a stronger associa-
tion was observed with estimated individual
residential THM4 concentration (µg/L) than
with individual ingestion of THM4 (µg/d) as
estimated by volume consumed multiplied by
tap-water THM4 concentration.
In the subset of genotyped individuals from
the SBCS in Cantor et al. (2010), bladder
cancer risks for average THM level (Table 5)
were similar to those reported in the original
study (Villanueva et al. 2007). Main effects for
genotypes demonstrated elevated bladder can-
cer risk among subjects carrying GSTM1 null
versus present, GSTT1 active versus null, and
NAT2 slow versus fast acetylator genotypes.
After consideration of THM exposure (Table 6),
significant bladder cancer risks increased with
exposure only among subjects with the GSTT12
active genotype, the CYP2E13 rs2031920 CC,
and the GSTZ14 rs1046428 CT/TT groups.
The rs2031920 C>T transition, also referred
to as the CYP2E∗5B allele, is associated with
enhanced gene transcription that would pro-
mote activation of low-molecular-weight com-
pounds and procarcinogens to reactive inter-
mediates (Wang et al. 2009). In contrast,
the GSTZ1T allele has lower enzymatic activ-
ity compared to the C allele to conjugate
and excrete dichloroacetic acid and related
metabolites (Blackburn et al. 2001). No evi-
dent relationship between bladder cancer and
THM exposure was observed among the low-
risk variant groups (Table 6). In instances where




HUMAN BLADDER CANCER AND CHLORINATION BY-PRODUCTS 221
TABLE 5. Bladder Cancer Odds Ratio in Relation to Residential
THM4 Exposure (Cantor et al. 2010 for Genotyped Cases, and




(95% CI) p Trend
≤8 µg/L 156/175 1.0
(reference)
>8.0–26.0 µg/L 153/174 1.2 (0.8–1.9)
>26.0–49 µg/L 197/169 1.8 (1.1–2.9)
>49 µg/L 174/196 1.8 (0.9–3.5) .029
values for interactions were generally significant
at the p < .05 level.
Cantor et al. (2010) found the most strik-
ing relationships with bladder cancer risk and
THM4 among a subset of 195 cases and
192 controls with the GSTT1 Present (active)
and GSTZ1 CT/TT genotypes. The subset of
subjects with combined genotype is small
and statistically underpowered for a study of
gene–gene-exposure interaction. The large OR
found, not surprisingly, attracted attention and
commentary (Freeman 2010). If similar associa-
tions are replicated in other study populations,
these would indicate the presence of geneti-
cally susceptible subpopulations that have com-
paratively higher bladder cancer risk upon
exposure to substances/compounds indicated
by THM4 exposure levels. Polymorphisms
in other pathways linked to metabolism of
CxDBP and similar chlorinated hydrocarbons
need to be included in such studies (e.g.,
cysteine beta-lyase; Moore et al. 2010).
However, with the exception of the GSTT1
enzyme, genotyping is not necessarily represen-
tative of functional enzymatic activity in spe-
cific tissues. Functional assays relating genetic
variants with enzyme activity will also be
required.
In summary, Cantor et al. (2010) provided
some important new findings that variation in
the genotypes of some enzymes involved in
CxDBP metabolism may identify subpopula-
tions of individuals exposed to CxDBPs (mostly
brominated compounds) who may be suscep-
tible to bladder cancer. Interpretation (and/or
extrapolation) of this evidence needs to be
done with caution until replicated in additional
exposed populations.
TABLE 6. Bladder Cancer Odds Ratio in Relation to Residential THM4 Exposure (Cantor et al. 2010) for Specified Genotype Comparisons
Average
THM4 measure








≤8 µg/L 1.0 (reference) 121/141 1.0 (reference) 34/34
>8.0–26.0 µg/L 1.2 (0.7–1.9) 116/136 1.2 (0.5–2.5) 36/37
>26.0–49 µg/L 2.0 (1.2–3.4) 160/126 1.2 (0.5–2.5) 37/41
>49 µg/L 2.2 (1.1–4.3) 145/147 1.0 (0.4–2.5) 29/48







≤8 µg/L 1.0 (reference) 52/62 1.0 (reference) 95/86
>8.0–26.0 µg/L 1.4 (0.7–2.7) 47/54 1.1 (0.7–1.9) 100/102
>26.0–49 µg/L 2.2 (1.1–4.2) 73/62 1.5 (0.9–2.7) 116/97
>49 µg/L 2.9 (1.3–6.7) 72/64 1.3 (0.6–2.8) 94/117




≤8 µg/L 1.0 (reference) 125/132 1.0 (reference) 15/9
>8.0–26.0 µg/L 1.3 (0.8–2.0) 133/141 0.98 (0.4–2.5) 10/14
>26.0–49 µg/L 2.1 (1.2–3.5) 176/134 1.1 (0.4–3.1) 9/11
>49 µg/L 2.0 (1.0–4.1) 156/162 0.6 (0.1–2.7) 3/8
p Trend .0014 .33 .035
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Secondary Studies
Salas et al. (2013) evaluated several other
metrics of exposure based on the original data
from the SBCS (Villanueva et al. 2007; Cantor
et al. 2010). The proportion of THM4 that
was brominated ranged from 35 to 84%, and
an estimated overall average value, weighted
according to the number of subjects reported
for each geographic region, demonstrated that
brominated THMs comprised almost 60% of
THM4 across 4 geographic regions of the 5 ana-
lyzed for bladder cancer risk in Villanueva et al.
(2007). Evidence indicated that the original
THM4 comparisons, rather than any measure
more specific to brominated DBPs, yielded the
strongest exposure-response relationship with
bladder cancer risk.
Costet et al. (2011) undertook a meta-
analysis to explore whether there was any
evidence of a different bladder cancer asso-
ciation with THMs for European versus North
American studies. Despite a substantial contri-
bution of the SBCS to the meta-analysis, data
demonstrated no marked difference in bladder
cancer risk for North American men in rela-
tion to European men. The North American
studies involved brominated THM levels that
are lower (e.g., Cantor et al. 1998: average
THM4 for the Iowa surface waters studied was
56 µg/L, whereas the average sum of the
bromine-containing THMs was only 10.4 µg/L,
19 wt%) than what was estimated in Villanueva
et al. (2006; 2007: 35–95 wt% in 4 Spanish
cities, including Asturias, which was low in bro-
mide impact relative to other Spanish cities
but still higher than in Iowa), such that the
Costet et al. (2011) comparisons are not con-
sistent with a mechanistic model based upon
a major role for brominated THMs or other
brominated compounds for which they may
serve as surrogates.
Nieuwenhuijsen et al. (2009) provided a
qualitative review of epidemiology and possible
mechanisms for adverse human health out-
comes that focused primarily on adverse repro-
ductive outcomes. However, epidemiologic
evidence (including Villanueva et al. [2007],
but not Cantor et al. [2010]) indicated
for drinking-water exposure, measured as
THMs, an “association” with bladder can-
cer that was “good,” but notably less con-
sistent epidemiologic associations for other
cancer sites. Limitations of these studies for
causal inference (vs. association) were not
directly addressed in the brief discussion of
epidemiologic studies addressing cancer out-
comes.
Experimental, Laboratory, and Shorter
Term Study Approaches
An interdisciplinary collaboration among
analytical chemists, toxicologists, and epidemi-
ologists explored what might be learned from
11 European water samples with respect
to epidemiologic and toxicologic responses.
Detailed chemical analyses were used to char-
acterize a wide range of DBPs and a suite of
short-term toxicology tests (Jeong et al. 2012).
Chemical analysis found more than 90 different
DBPs among the 11 samples, with THM4 and
the sum of 9 HAAs (HAA9) dominant on a mass
concentration basis, as would be expected.
A clear difference was found in the genotoxic
responses among the samples, but these dif-
ferences in genotoxic results did not corre-
late well with chemical analyses to reveal any
explanation of genotoxicity in terms of specific
CxDBP(s) being present.
Given the challenges posed by retrospective
exposure assessment and latency for study-
ing human bladder cancer association with
CxDBPs, the use of intermediate markers of
effect may prove useful. One option that has
been evaluated for determining exposure to
carcinogens, including arsenic, has been human
biomonitoring to measure micronucleus (MN)
formation (Warner et al. 1994; Moore et al.
1996). This has particular appeal for studying
bladder cancer because bladder epithelial cells
are exfoliated in urine, providing a feasible sam-
pling approach. Similarly, current exposures are
easily measured and subjects may be selected
to include a large variation in exposure using
biomonitoring (Kogevinas et al.2010).
Ranmuthugala et al. (2003) reported an
experimental study using MN that was well
conceived in terms of comparative CxDBP
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exposure scenarios. Although 348 males com-
pleted the full protocol, no significant associ-
ation between MN prevalence and any mea-
sure of THM exposure was found. However,
the higher occurrence of smokers in the com-
munity having no THM4 exposure effectively
reduced study sensitivity, as smoking may have
confounded the results.
Villanueva et al. (2007) included a sub-
study of a sample of 44 female controls
that had THM4 exposure data, but signifi-
cant associations were not observed. The study
was likely statistically underpowered. Further,
female exfoliated cells in urine consist of only a
small percentage of transitional cells associated
with transitional-cell carcinoma (i.e., bladder
cancer) and are predominantly squamous cells
of the bladder trigone (Schulte et al. 1963; Tyler
1962).
Subsequently, Kogevinas et al. (2010) stud-
ied a volunteer cohort of 49 adult, nonsmok-
ing swimmers from a group of 17 males and
33 females in Barcelona, who were monitored
for individual THMs in exhaled breath. Changes
in MN prevalence and DNA damage (comet
assay) were measured in peripheral blood lym-
phocytes (PBL) before and 1 h after swimming.
Urine mutagenicity (Ames assay) was measured
before and 2 h after swimming, and exfoli-
ated MN were measured before and 2 wk after
swimming. The last analysis was likely too soon
after swimming to expect urothelium to change
and shed MN. Kogevinas et al. (2010) found
significant increases in genotoxicity in PBL, but
no significant associations with changes in MN
urothelial cells. Having females as 66% of the
study group was also a limitation of a study
focused on urothelial cells.
A major series of experimental studies
was undertaken by the U.S. EPA to eval-
uate complex mixtures of DBPs. Simmons
et al. (2008) outlined the scientific rationale
used for planning the experimental proto-
cols used in what was described as the Four
Lab Study. Richardson et al. (2008) described
the comprehensive chemical analyses of the
treated drinking-water concentrates developed
for these experiments. Claxton et al. (2008)
evaluated Salmonella mutagenicity and Crosby
et al. (2008) evaluated the gene expression in
rat hepatocytes for these Four Lab Study con-
centrates. Rice et al. (2009) and Bull et al.
(2009) assessed the ability to compare the com-
position of DBP mixtures and Schenk et al.
(2009) evaluated correlation of DBP mixture
composition with Salmonella mutagenicity.
Cancer Risk Assessment
Bull (2012) considered Cantor et al. (2010)
and argued why those results alone cannot
establish THMs as being responsible for the
observed bladder cancer risk. Bull (2012) also
argued against the Cantor et al (2010) data
necessarily implicating THMs based on compar-
ison of CYP2E1 and GSTT1 activity. However,
the Bull (2012) analysis considered GSTT1
enzyme activity in rodents derived from Ross
and Pegram (2004), which cannot necessarily
be extrapolated to humans.
The conceptual inhalation–dermal expo-
sure model that was proposed by Pegram and
described in Richardson et al. (2007) received
support from a number of studies (Ross and
Pegram 2003; 2004; Leavens et al. 2007;
Pegram et al. 1997; DeMarini et al. 1997;
Kundu et al. 2004; Landi et al. 1999). However,
there are no apparent human data for the
metabolic activity of CYP2E1 and GSTT1 for
THMs that bypass the liver (via inhalation or
dermal exposure) for other tissues, such as blad-
der, lung, or possibly kidney. Without these
human data, the Bull (2012) critique of this
model cannot be resolved. The Pegram (per-
sonal communication 2014) model also did not
consider other routes of exposure or other, non-
volatile CXDBPs, such as HAAs that may be
metabolized by GSTZ1. The conceptual mech-
anistic model in Cantor et al. (2010) provides
a different risk perspective that needs further
investigation. Detailed insights are limited by
the reality that there are no long-term cancer
bioassays suitable for supporting quantitative
cancer risk assessments that evaluate inhala-
tion or dermal exposure to any of the bromi-
nated CxDBPs. Physiologically based pharma-
cokinetic (PBPK) modeling may provide some
additional insights for these issues.
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Cancer risk assessment using animal bioas-
says studying carcinogenic agents follows an
entirely different paradigm based on entirely
different evidence than the prediction of
human cancer cases by means of human
epidemiology studies. However, attribution of
observed human cancers to agents like CxDBPs
in drinking water, whether individually or in
some combination, would be strengthened by
finding some concordance in the cancer risk
predictions by these disparate approaches.
Bull (2012) and Bull et al. (2011) tack-
led this comparison, including cancer risk
predictions for more potent mutagenic
DBPs like brominated dihaloacetic acids
and dihaloacetonitriles, and 3-chloro-4-
(dichloromethyl)-5-hydoxy-2(5H)-furanone
(MX) with brominated analogues and N-
nitrosodimethylamine (NDMA) to conclude
that the latter summation for all-cancer site
risk is 100-fold lower than the epidemiologic,
site-specific bladder cancer risk estimates.
These discrepancies in cancer risk predictions,
notwithstanding the differences in approaches,
are indicative of the evidence gaps and quan-
titative uncertainties inherent in the current
evidence base.
CONCLUSIONS
The evidence for associations between
bladder cancer and CxDBPs are primarily
reliant on 10 case-control studies, with the
most recent original case data collection from
prior to 2001 (Villanueva et al. 2007; Cantor
et al. 2010). The other case-control studies
have cases mostly from a decade earlier, which
may reflect effects of earlier, higher expo-
sures prior to implementation of THM regu-
lations. Replication in other populations with
exposures reflecting more recent levels with
current exposures, and utilizing other study
designs (e.g., cohort studies), may provide addi-
tional evidence for judging a causal association
between CxDBP exposure and bladder cancer
under current exposure scenarios. Improved
exposure and genetic susceptibility assessments
would ideally be a part of these newer studies.
To specifically evaluate the impact of the Stage
2 DBP Rule on bladder cancer incidence in the
United States, future studies are required that
account for both the lower CxDBP levels associ-
ated with the rule implementation, and passage
of sufficient time to account for bladder cancer
latency.
Strengths and Limitations of the Evidence
for Linking CxDBPs and Bladder Cancer
Strengths are:
• There are 2 cohort studies and 10 case-
control studies using various indicators
of exposure to CxDBPs or exposure to
chlorinated surface water. Among the case-
control studies, 8 suggested an association
with bladder cancer, with significant ORs for
men ranging from about 1.4 to 2.5. Table 7
summarizes these studies and shows the con-
sistency of associations noted with bladder
cancer.
• There are two meta-analyses (Villanueva
et al. 2003a; Costet et al. 2011) of case-
control studies that provide some consis-
tency and support for an association of
CxDBPs with bladder cancer. A pooled anal-
ysis (Villanueva et al. 2004) found similar
associations.
• The Villanueva et al. (2007) study based on
the comparatively large Spanish case-control
study from 1998 to 2001 included explicit
exposure categories of showering/bathing
and swimming. Observed associations sup-
port a conceptual model that suggests that
inhalation/dermal exposure to CxDBPs may
be at least as important for bladder cancer
risk as ingestion.
• The Villanueva et al. (2007) study also
included explicit exposure to CxDBPs with
a majority proportion of brominated species
(Villanueva et al. 2003b). Observed asso-
ciations are stronger than found previ-
ously in North American studies, sug-
gesting that brominated species might be
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• A conceptual model involving GSTT1 devel-
oped around several toxicological investiga-
tions (Richardson et al. 2007; Pegram per-
sonal communication 2014), combined with
the findings of Villanueva et al. (2007),
involves a number of plausible elements that
collectively raise the conceptual model above
that of simply being a possibility. However,
the model is currently short of providing a
probable explanation of the epidemiologic
observations.
• Cantor et al. (2010) evaluated a subset of the
Villanueva et al. (2007) subjects according to
a number of candidate genes with variation
in several single nucleotide polymorphisms
(SNPs), some of which were selected with the
conceptual model of Pegram (personal com-
munication 2014; Richardson et al. 2007)
in mind. These results provide a possible
mechanistic basis for the association with
bladder cancer; however, the specific tie
to THMs or other volatile DBPs needs to
be established and the genetic susceptibility
results require replication in an independent
population.
Limitations are:
• Of the 10 case-control studies already men-
tioned, 2 (Cantor et al. 2010; Villanueva
et al. 2007) are different analyses of the
same case-control study, and 3 (Bove et al.
2007; Chevrier et al. 2004; McGeehin et al.
1993) have size or methodological issues that
reduce the weight that can be placed on
their findings as sources of replication for the
purposes of judging consistency.
• The two meta-analyses (Villanueva et al.
2003; Costet et al. 2011) involve six case-
control studies in common. The pooled anal-
ysis (Villanueva et al. 2004) includes three of
the case-control studies among the six used
in the two meta-analyses.
• For the genetic factors studied by Cantor et al.
(2010), the specific tie to THMs or other
volatile DBPs needs to be established and
there is an absolute need for replication of
results in another setting with independent
populations before confidence can be placed
in these findings.
• The differing views between Bull (2012) and
Pegram (personal communication 2014) on
the causal role of THMs according to the con-
ceptual inhalation/dermal exposure model
underlying Cantor et al. (2010) will not
be resolved without some additional direct
human evidence.
• The impact of a high proportion of brominated
DBPs involved in Villanueva et al. (2007) was
not noted in the meta-analysis of Costet et al.
(2011), although two other European studies
reported no information on brominated DBPs.
The North American epidemiologic studies
examined waters without such high levels of
bromide and brominated DBPs as found in the
Spanish study (Villanueva et al. 2006; 2007).
THM4, chloroform in particular, may be serv-
ing as a surrogate for an as-yet-unidentified
causal agent.
• CxDBP epidemiologic studies that used esti-
mates of past THM levels, with the exception
of the CxDBP exposure reanalyses performed
by Amy et al. (2006), estimated CxDBP expo-
sure levels in the distant past by extrapolating
back in time based on current or recent mea-
surements. These extrapolations did not take
into account changes in treatment practices
over time, such that past CxDBP exposures
are likely underestimated. As a result, where
associations with bladder cancer are found,
those associations will be reported to occur
for lower CxDBP exposures than were likely
experienced.
• There is a quantitative discrepancy between
epidemiologic site-specific risk estimates for
bladder cancer from THM4 and what can be
estimated by summing all the upper-bound,
all-cancer-site risk predictions from applica-
tion of cancer slope factors for individual
genotoxic CxDBPs. This analysis has not been
conducted with all the emerging CxDBPs that
may be of higher health concern than the reg-
ulated CxDBPs because most of the former
do not have estimated cancer slope factors.
Two genotoxic CxDBPs (MX, NDMA) that
were included have cancer slope factors that
are orders of magnitude more potent than
the THMs or HAAs but they also occur at
ordersofmagnitude lowerconcentrations than
THM4 or HAA9.
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Knowledge Gaps
• THM4 has been evaluated in many
epidemiologic studies because of the
availability of these monitoring data; how-
ever, it is not possible using these studies to
determine whether THM4 or some correlate
is an etiologic factor associated with bladder
cancer.
• For the genetic factors studied by Cantor
et al. (2010), there is an absolute need for
replication of results in another setting with
independent populations before confidence
can be placed in these findings.
• The differing views between Bull (2012) and
Pegram (personal communication 2014) on
the causal role of THMs according to the con-
ceptual inhalation/dermal exposure model
underlying Cantor et al. (2010) will not
be resolved without some additional direct
human evidence (see discussion on cancer
risk assessment).
Evidence Supporting Better Risk
Management
The available new evidence does not
clearly or adequately indicate what changes
to DBP quantitative limits would be benefi-
cial for the United States. The evidence opens
possibilities of new hazard identification (e.g.,
brominated compounds, many of the other
nonregulated DBPs, inhalation/dermal expo-
sure). There are opportunities to inform a better
understanding of CxDBP exposures, but any
causative CxDBP agents for bladder cancer
have not yet been identified.
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